• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Children's National Urea Cycle Disorders Consortium awarded $6M by NIH

Children's National Urea Cycle Disorders Consortium awarded $6M by NIH

October 13, 2014
CenterWatch Staff

Children's National Health System's Urea Cycle Disorders Consortium, based in Wash. D.C., was awarded $6.25 million over the next five years from the NIH to perform clinical research and develop new treatments for patients with urea cycle disorders (UCD), which are rare but devastating genetic conditions.

Mark L. Batshaw, M.D., physician-in-chief and chief academic officer at Children's National, is the Principal Investigator for the program. Mendel Tuchman, M.D., chief research officer and scientific director of the Children's Research Institute, is the administrative director and co-Principal Investigator of the Urea Cycle Disorders Consortium. Marshall Summar, M.D., chief of genetics and metabolism at Children's National and Cynthia LeMons, president of the National Urea Disorders Foundation, are co-Principal Investigators.

Since its inception in 2003, the Urea Cycle Disorders Consortium has received matching philanthropic support from the O'Malley Family Foundation, the Kettering Fund, theĀ Dieter-Hopp Foundation and the Rotenberg Family Foundation.

"The Consortium has assisted in bringing three new drugs to market to treat these devastating disorders that primarily affect children, leading to brain injury and often death," said Batshaw.

There are several thousand rare diseases affecting 25 million Americans, but only a few hundred diseases have any treatments available. Tuchman indicated that "the creation and funding of the Urea Cycle Disorders Consortium has been the culmination of many years of clinical and research work by our group to improve the lives of children and adults with rare metabolic disorders."

With the new award, scientists at the consortia will test new therapies and continue to conduct a longitudinal natural history study of affected patients to better understand the course of the disorders. The consortium has more than 650 participants enrolled in studies, ten times more than any previous study conducted in this group of rare disorders, Batshaw said.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing